Short Interest in UCB SA (OTCMKTS:UCBJF) Increases By 20.8%

UCB SA (OTCMKTS:UCBJF) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 481,000 shares, a growth of 20.8% from the February 28th total of 398,200 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 3,100 shares, the short-interest ratio is presently 155.2 days.

UCB Stock Performance

UCBJF stock opened at $174.30 on Friday. The company has a 50-day simple moving average of $190.30 and a 200 day simple moving average of $186.24. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a fifty-two week low of $123.00 and a fifty-two week high of $209.66.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.